Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Receivables - Other: 2010-2024

Historic Receivables - Other for Arrowhead Pharmaceuticals (ARWR) over the last 7 years, with Dec 2024 value amounting to $2.5 million.

  • Arrowhead Pharmaceuticals' Receivables - Other was N/A to $2.5 million in Q4 2024 from the same period last year, while for Dec 2024 it was $2.5 million, marking a year-over-year change of. This contributed to the annual value of $4.8 million for FY2022, which is 52.00% down from last year.
  • As of Q4 2024, Arrowhead Pharmaceuticals' Receivables - Other stood at $2.5 million, which was up 66.67% from $1.5 million recorded in Q2 2023.
  • Arrowhead Pharmaceuticals' 5-year Receivables - Other high stood at $25.0 million for Q4 2022, and its period low was $100,000 during Q4 2021.
  • Moreover, its 3-year median value for Receivables - Other was $2.5 million (2024), whereas its average is $7.0 million.
  • Its Receivables - Other has fluctuated over the past 5 years, first crashed by 98.78% in 2021, then spiked by 24,900.00% in 2022.
  • Arrowhead Pharmaceuticals' Receivables - Other (Quarterly) stood at $8.2 million in 2020, then plummeted by 98.78% to $100,000 in 2021, then surged by 24,900.00% to $25.0 million in 2022, then reached $1.5 million in 2023, then reached $2.5 million in 2024.
  • Its Receivables - Other was $2.5 million in Q4 2024, compared to $1.5 million in Q2 2023 and $25.0 million in Q4 2022.